FDA Rebuffs Alimera Diabetes Eye Treatment Over Concerns

Law360, New York (October 18, 2013, 5:19 PM EDT) -- U.S. regulators have rejected Alimera Sciences Inc.’s eye implant treatment for diabetes patients, citing concerns about its safety as well as potential issues at the facility where the implant is manufactured, the Georgia-based pharmaceutical firm said Friday.

The decision by the U.S. Food and Drug Administration came in response to Alimera’s New Drug Application for its Iluvien eye implant to treat diabetic macular edema, a condition that causes swelling within the eye, which diabetes patients may experience, the company said in a statement. The FDA sent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.